855894-11-0

Upstream product

• 109-01-3 1-methyl-piperazine 
• 1746-28-7 1-bromo-4-(2-bromoethyl)benzene 
• 50-00-0 formaldehyd 
• 1007400-20-5 C₅H₁₂N₂*C₂HF₃O₂ 
• 115055-85-1 bromo-[(4-bromophenyl)methyl]zinc 
• 84913-19-9 4-methylbenzene sulfonic acid 2-(4-bromophenyl)ethyl ester 
• 4654-39-1 4-bromophenethanol 
• 1878-68-8 2-(4-bromophenyl)-acetic acid 
• 349430-56-4 2-(4-bromophenyl)-1-(4-methylpiperazin-1-yl)ethan-1-one 

Downstream Products

• 1410789-59-1 α-{4-[2-(4-methyl-1-piperazinyl)ethyl]phenyl}-α-phenyl-1-tricyclo[3.3.1.1^3,7]decanemethanol 
• 1410790-06-5 C₃₀H₄₀N₂ 
• 1089127-87-6 7(S)-7-deoxy-7-(4-(2-(4-methylpiperazin-1-yl)ethyl)phenylthio)lincomycin 
• 1394862-53-3 C₃₈H₄₄N₆O₂ 

Relevant academic research and scientific papers

Novel 3-(substituted amino)-6-alkyl-pyrazine-2-carboxamide derivatives and use thereof

A novel 3 -6 - alkyl-pyrazine -2 - carboxamide derivative or a pharmaceutically acceptable salt thereof. A pharmaceutical composition for preventing or treating MerTTK-related diseases and a method for preventing or treating MerTTK-related diseases contains the same as an active ingredient.

PYRROLO [2, 3-B] PYRIDINES OR PYRROLO [2, 3-B] PYRAZINES AS HPK1 INHIBITOR AND THE USE THEREOF

Disclosed herein is a compound of Formula (AIII) or (III), or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions comprising thereof. Also disclosed is a method of treating HPK1 related disorders or diseases by using the compound disclosed herein.

New adamantane phenylalkylamines with σ-receptor binding affinity and anticancer activity, associated with putative antagonism of neuropathic pain

The synthesis of the adamantane phenylalkylamines 2a-d, 3a-c, and 4a-e is described. These compounds exhibited significant antiproliferative activity, in vitro, against eight cancer cell lines tested. The σ1, σ2, and sodium channel binding affinities of compounds 2a, 3a, 4a, and 4c-e were investigated. The most interesting analogue, 4a, exhibited significant in vivo anticancer profile on pancreas, prostate, leukemia, and ovarian cancer cell line xenografts together with apoptosis and caspase-3 activation. Inhibition of the cancer cells cycle at the sub-G1 level was also obtained with 4a. Finally, encouraging results were observed with 4a in vivo on mice, suggesting putative antimetastatic and analgesic activities of this compound.

LINCOMYCIN DERIVATIVES AND ANTIBACTERIAL AGENTS CONTAINING THE SAME AS THE ACTIVE INGREDIENT

An objective of the present invention is to provide compounds of formula (1) or their pharmacologically acceptable salts or solvates wherein A represents aryl; R1 represents N-optionally substituted C1-6 alkyl-N-optionally substituted C1-6 alkylamino-C1-6 alkyl; R2 represents a hydrogen atom or optionally substituted C1-6 alkyl; R3 represents optionally substituted C1-6alkyl or C3-6 cycloalkyl-C1-4 alkyl; m is 1 to 3; n is 0; and p is 0 to 2. The compounds are novel lincomycin derivatives that have a potent activity against resistant Streptococcus pneumoniae, which have recently posed problems, in the treatment of infectious diseases. Further, the compounds are usable as antimicrobial agents and are useful for preventing or treating bacterial infectious diseases.

Synthesis and Src kinase inhibitory activity of 2-phenyl- and 2-thienyl-7-phenylaminothieno[3,2-b]pyridine-6-carbonitriles

2-Phenyl-7-phenylaminothieno[3,2-b]pyridine-6-carbonitriles were recently reported to be inhibitors of Src kinase activity. In this study we present structure-activity relationships for additional thieno[3,2-b]pyridine-6- carbonitriles, modifying the subs